Meeting Banner
Abstract #4203

Pharmacological MRI with T1 Contrast Agents

Richard Baheza 1 , Nellie Byun 2 , Adam Stark 3 , and John C. Gore 3,4

1 RADIOLOGY AND RADIOLOGICAL SCIENCES, Vanderbilt University Medical Center, NASHVILLE, TN, United States, 2 PHARMACOLOGY, Vanderbilt University Medical Center, NASHVILLE, TN, United States, 3 VANDERBILT UNIVERSITY INSTITUTE OF IMAGING SCIENCE, Nashville, TN, United States, 4 BIOMEDICAL ENGINEERING, Vanderbilt University, Nashville, TN, United States

We performed whole brain pharmacological MRI (phMRI) at 9.4T with the FDA approved T1 contrast agent Magnevist using an optimized 3D acquisition sequence to detect amphetamine-induced brain activity in rats. Increasing the psychostimulant dose from 2.0 to 4.0 mg/kg elevated the acquired signal increases from 1.870.55% to 4.710.33% in the caudate-putamen, demonstrating that the method is sensitive to drug concentration. These data validate the utility of using a T1 shortening agent with 3D acquisition for phMRI. This method has translational potential to clinical drug studies using FDA-approved contrast agents.

This abstract and the presentation materials are available to members only; a login is required.

Join Here